Biomarkers for Predicting Clinical Outcomes of Chemoradiation-Based Bladder Preservation Therapy for Muscle-Invasive Bladder Cancer.

Int J Mol Sci · 2018 · PMC6165010 · PMID 30223570

Europe PMC DOI

hedged sentence

0.0700

closest p · 1.4× alpha

0.0700

boldest claim

The sentences

showed a trendp = 0.070so close (0.05 < p ≤ 0.1)

The presence of DDR gene alterations, most commonly identified in ERCC2 , showed a trend for better bladder or metastatic recurrence-free survival (HR 0.47, p = 0.070); this finding is in line with studies on neoadjuvant chemotherapy for MIBC [ 48 , 49 ] and systemic chemotherapy for advanced urothelial carcinoma [ 50 ], showing significantly better clinical outcomes for tumors with DDR gene alterations.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.